Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF (HBV)
Study on Three Types of Nucleotide/Nucleoside Analogues Treatment in Patients With Hepatitis b Virus Related Acute-on-chronic Liver Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Liang Peng, Doctor
- Phone Number: +8613533978874
- Email: pzp33@hotmail.com
Study Contact Backup
- Name: Wenxiong Xu, Doctor
- Phone Number: +8613760783281
- Email: xwx1983@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510630
- Recruiting
- Third Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Liang Peng, Doctor
- Phone Number: +8613533978874
- Email: pzp33@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Positive hepatitis b surface antigen or hepatitis b virus DNA > 0.5 year;
- Age from 12 to 65 years old;
- Serum total bilirubin level > 10 times upper limit of normal;
- Prothrombin time activity < 40% or prothrombin time international ratio > 1.5;
- Do not receive nucleotide/nucleoside analogues treatment in the past half year.
Exclusion Criteria:
- Other active liver diseases;
- Hepatocellular carcinoma or other malignancy;
- Pregnancy or lactation;
- Human immunodeficiency virus infection or congenital immune deficiency diseases;
- Severe diabetes, autoimmune diseases;
- Other important organ dysfunctions;
- Using glucocorticoid;
- Patients can not follow-up;
- Investigator considering inappropriate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: ETV group
50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
|
Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
Other Names:
|
|
Active Comparator: TDF group
50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
|
Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
Other Names:
|
|
Experimental: TAF group
50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
|
Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival rate in the follow-up
Time Frame: 144 week
|
Whether patients will survive after treatment is observed in the follow-up.
|
144 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ratio of patients with undetectable hepatitis b virus DNA after treatment
Time Frame: 4 week, 8 week, 12 week, 24 week, 48 week, 72 week,144 week
|
Hepatitis b virus DNA would be tested to know the ratio of patients with undetectable hepatitis b virus DNA at 7 time points after treatment.
|
4 week, 8 week, 12 week, 24 week, 48 week, 72 week,144 week
|
|
Model for end-stage liver disease (MELD) score is recorded after treatment
Time Frame: 0 week, 4 week, 8 week, 12 week, 24 week, 48 week, 72 week,144 week
|
The calculation of model for end-stage liver disease (MELD) score is: R=0.378ln[serum total bilirubin (mg/dl)]+1.12ln(prothrombin
time international normalized ratio)+0.95ln[serum
creatinin(mg/dl)]+0.64.
The higher the MELD score, the higher the mortality rate.
MELD score is recorded after treatment.
|
0 week, 4 week, 8 week, 12 week, 24 week, 48 week, 72 week,144 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Liang Peng, Doctor, Third Affiliated Hospital, Sun Yat-Sen University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Infections
- RNA Virus Infections
- Virus Diseases
- Digestive System Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Communicable Diseases
- DNA Virus Infections
- Hepadnaviridae Infections
- Liver Failure, Acute
- Hepatitis A
- Hepatitis
- Hepatitis B
- End Stage Liver Disease
- Liver Failure
- Hepatic Insufficiency
- Acute-On-Chronic Liver Failure
- Anti-Infective Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
- Entecavir
Other Study ID Numbers
Other Study ID Numbers
- PL6
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.